Erenumab Offers Relief for MOH in Chronic Migraine
TOPLINE: Erenumab, injected monthly at 140 mg, can effectively induce remission of nonopioid medication overuse headache (MOH) in patients with chronic migraine within 6 months. The treatment also significantly reduces the number of acute headache …